| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 53.77 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Varenicline, a partial agonist selective for a4b2 nicotinic acetylcholine receptor subtypes, was approved in 2006 by the FDA as an aid for smoking cessation in association to counselling.
Since its commercialization, many individual cases reported psychiatric adverse effects on patients prescribed with varenicline− such as depressive mood, anxiety, suicidal ideation or even suicidal attempt. Subsequently, the FDA required the addition of a Boxed Warning to this drug. It is believed this reports leaded to
some apprehension on its prescription [1].
Description
Keywords
Pedagogical Context
Citation
Rodrigues, Carina.; Andrade, M.; Bettencourt, M.; Palma, V.; Cardoso, C. (2016). Varenicline suicidal ideation in psychiatric patients − a case report and systematic review. European Neuropsychopharmacology. ISSN 0924-977X. 26, S710-S710
Publisher
Elsevier